Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.

Perlecan domain V inhibits alpha2 integrin-mediated amyloid-beta neurotoxicity.

Wright S., Parham C., Lee B., Clarke D., Auckland L., Johnston J., Lawrence A.L., Dickeson S.K., Santoro S.A., Griswold-Prenner I., Bix G.

Amyloid-β (Aβ) peptide is a key component of amyloid plaques, one of the pathological features of Alzheimer's disease. Another feature is pronounced cell loss in the brain leading to an enlargement of the ventricular area and a decrease in brain weight and volume. Aβ plaque deposition and neuronal toxicity can be modeled by treating human cortical neuronal cultures with Aβ and showing robust Aβ deposition and neurotoxicity that is mediated by α2β1 and αvβ1 integrins. The current study expands on these findings by showing that the domain V of perlecan, a known α2 integrin ligand, inhibits Aβ neurotoxicity in an α2 integrin-dependent manner. Additionally, Aβ binds more efficiently to cells expressing activated α2 integrin. Finally the inhibition of Aβ neurotoxicity with domain V is synergistic with inhibitors of αv integrin and β1 integrin. We propose that domain V and potentially other α2 integrin ligands could be a new therapeutic approach for inhibiting the Aβ plaque deposition and neurotoxicity observed in Alzheimer's disease.

Neurobiol. Aging 33:1379-1388(2012) [PubMed] [Europe PMC]